Biotie Therapies Oy

FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization. “I am delighted to welcome Mitch and Angie to the team. They are industry leaders with a proven track record of success in building both public and private biopharma companies. As Attovia looks toward our next stage of growth and drives our mission of bringing forward first-in-class and best-in-class therapies against immune-mediated disease, their expertise will be invaluable in supporting the business and strategic priorities of the company,” said Tao Fu, Chief Executive Officer of Attovia Therapeutics. Dr. Gold was chairman, CEO, and founder of Alpine Immune Sciences, a publicly traded biotech company (Nasdaq: ALPN) dedicated to developing innovative treatments for autoimmune and inflammatory diseases, that was acquired by Vertex Pharmaceuticals in May of 2024 for $4.9 billion. Previously, he was a board member and former president and CEO of Dendreon Corporation, which under his leadership brought the therapeutic cancer vaccine Provenge® through late-stage development and regulatory approval in 2010 as the world’s first FDA-approved active cellular cancer immunotherapy. Dr. Gold also serves as the managing partner of Alpine BioVentures, a healthcare focused investment fund. Dr. Gold graduated from the University of Wisconsin and Rush University Medical School in Chicago, and was a urology resident at the University of Washington. Dr. You is currently the CEO of Architect Therapeutics and serves on the Board of Directors of ORIC Pharmaceuticals (Nasdaq: ORIC). Prior to Architect, Dr. You served as CEO of Amunix Pharmaceuticals, where she orchestrated the acquisition of the company by Sanofi for over $1.2 billion. Prior to joining Amunix, Dr. You served as Chief Business & Strategy Officer and Head of Commercial at Sierra Oncology from 2014 to 2018, where she helped the company through a successful initial public offering and led the company’s business and commercial efforts. Prior to Sierra Oncology, Dr. You served as Chief Business Officer of Aragon Pharmaceuticals from 2010 through its acquisition by Johnson & Johnson in 2013. In previous roles, Dr. You served as Chief Business Officer at Synosia Therapeutics and Ren Pharmaceuticals, worked on new company formation at Venrock Ventures, and served on the Board of Directors of RayzeBio prior to its acquisition by Bristol Myers Squibb. Dr. You earned a Ph.D. in biochemistry from Harvard University and a B.A. in chemistry from Harvard College. “I’m excited to join the Attovia Board as the company prepares for first-in-human clinical trials for its lead program and expands its portfolio of multi-specific therapeutics against immune-mediated disease,” said Dr. Gold. “The Company has made significant progress since its inception and I look forward to supporting its goal of building an I&I leader with innovative medicines.” Dr. You added, “The potential of ATTOBODIES to offer first-in-class and best-in-class therapeutics through their ‘IgG-alternative’ properties positions Attovia to drive real change in patients’ lives. The Company has built a strong team, is well capitalized, and is poised for transformational growth, including opportunities to leverage partnerships to realize the potential of its technology.” About Attovia Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages ATTOBODY™, a novel biologics platform, to generate small format biparatopic binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. Learn more at attovia.com. About ATTOBODY™ ATTOBODIES are small format biparatopic biologics that utilize a proprietary spatial positioning technology to unlock a new dimension of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, which drives strong potency in biologic activity, and functionalizes biologically inactive epitopes. ATTOBODIES are modular, can be engineered into multispecifics, and offer tunable half-life from hours to weeks. The high-throughput, evolution-based ATTOBODY discovery platform significantly accelerates development and offers a high degree of diversity in lead candidates, expanding target biology coverage and derisking development. Press Contact Attovia Therapeutics: info@attovia.com

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You currently serves as chief executive officer of Amunix Pharmaceuticals, Inc. “We are delighted to welcome Angie to ORIC’s board of directors,” said Jacob Chacko, M.D., president and chief executive officer. “Angie’s broad experience spanning venture capital, a variety of business development transactions, and public company leadership will bring valuable expertise and insight to ORIC as we continue to build and advance our pipeline of novel oncology candidates toward potential clinical proof of concept and commercialization.” Dr. You joined Amunix Pharmaceuticals as chief executive officer of in 2018. Prior to joining Amunix, Dr. You served as chief business & strategy officer and head of commercial at Sierra Oncology (Nasdaq: SRRA), where she led the company’s strategic and transactional business and commercial efforts, including building its robust pipeline through acquisition and licensing of several product assets. Prior to Sierra Oncology, Dr. You served as chief business officer of Aragon Pharmaceuticals. In previous roles, Dr. You served as chief business officer at Synosia Therapeutics and Ren Pharmaceuticals. Before joining Ren Pharmaceuticals, Dr. You focused on new company formation at Venrock Ventures. Dr. You earned a Ph.D. in Biochemistry from Harvard University and a B.A. in Chemistry from Harvard College. Dr. You added, “I have watched with interest as Jacob and the highly experienced ORIC leadership team have used both cutting-edge internal drug discovery and targeted business development to build an impressive pipeline of promising oncology candidates to treat a range of cancers. I am excited to join the board and look forward to working with the leadership team to support the next phase of growth and evolution of the company.” Concurrent with the appointment of Dr. You, Carl L. Gordon, Ph.D., CFA, founding and managing partner at OrbiMed, resigned from ORIC’s board. Dr. Chacko stated, “I would like to thank Carl for his guidance, support, and partnership during his tenure on the ORIC board dating back to his initial investment in our Series B in 2015. On behalf of the entire ORIC Board and leadership team, we are incredibly grateful to Carl for his many contributions to ORIC that have positioned us well to achieve our mission of improving patients’ lives by overcoming resistance in cancer.” About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials in combination with (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to , and follow us on Twitter or LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding development of the Company’s product candidates and statements by the company’s president and chief executive officer or board members. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC-101, ORIC-533, ORIC-944, ORIC-114 or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of the COVID-19 pandemic on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license agreements; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2021, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investor Contact: Dominic Piscitelli, Chief Financial Officer dominic.piscitelli@oricpharma.com info@oricpharma.com

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE December 22, 2015 at 10.30 a.m. Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the "Company") has on December 21, 2015 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Mr. Seth Klarman on behalf of himself, SAK Corporation and The Baupost Group, L.L.C. as a result of the implementation of changes to the transparency directive in the Finnish Securities Market Act. According to the notification, the total number of Biotie shares owned directly or through financial instruments by Seth Klarman and entities under his control was 15.89 per cent of Biotie's total number of shares and voting rights on November 26, 2015. Biotie's registered total number of shares and voting rights amounting to 1,086,940,271 has been used in the calculation of percentages for the announcement. Total positions of Seth Klarman and entities under his control subject to the notification: % of shares and voting rights (total of A) % of shares and voting rights through financial instruments (total of B) Total of both in % (A + B) Resulting situation on the date on which threshold was crossed or reached 13.08 2.81 15.89 Position of previous notification (if applicable) 10.21 N/A N/A Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shares and voting rights Class/type of sharesISIN code (if possible) Number of shares and voting rights % of shares and voting rights Direct (SMA 9:5) Indirect (SMA 9:6 and 9:7) Direct (SMA 9:5) Indirect (SMA 9:6 and 9:7) Shares (FI0009011571) - 30,555,556 - 2.81 Shares(FI0009011571)represented by 1,395,000 ADSs - 111,600,000 - 10.27 SUBTOTAL A 142,155,556 13.08 For further information on the ADSs representing the Company's shares, the notification refers to the stock exchange release issued by the Company on June 11, 2015. B: Financial instruments according to SMA 9:6a Type of financial instrument Expiration date Exercise/ Conversion period Physical or cash settlement Number of shares and voting rights % of shares and voting rights Warrants entitling to shares (new or treasury shares) (FI0009011571) Nov 1, 2020 Nov 1, 2015 - Nov 1, 2020 Physical settlement 30,555,556 2.81 SUBTOTAL B 30,555,556 2.81 For further information on the warrants, the notification refers to the stock exchange release issued by the Company on April 23, 2015. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both Seth Klarman 0 0 0 SAK Corporation 0 0 0 The Baupost Group, L.L.C. 0 0 0 Baupost Private Investments A-1, L.L.C. 1.28 0.28 1.56 Baupost Private Investments B-1, L.L.C. 0.51 0.11 0.62 Baupost Private Investments C-1, L.L.C. 2.90 0.63 3.52 Baupost Private Investments H-1, L.L.C. 0.92 0.20 1.13 Baupost Private Investments P-1, L.L.C. 0.48 0.10 0.58 Baupost Private Investments Y-1, L.L.C. 0.34 0.07 0.41 Baupost Private Investments BVI-1, L.L.C. 0.82 0.18 0.99 Baupost Private Investments BVII-1, L.L.C. 1.02 0.22 1.24 Baupost Private Investments BVIII-1, L.L.C. 0.41 0.09 0.50 Baupost Private Investments BVIV-1, L.L.C. 4.40 0.94 5.34 According to the notification, Seth Klarman is the sole owner of SAK Corporation, the manager and controlling entity of The Baupost Group, L.L.C., which is the managing general partner of (i) Baupost Limited Partnership 1983 A-1 (being the parent entity of Baupost Private Investments A-1, L.L.C), (ii) Baupost Limited Partnership 1983 B-1 (being the parent entity of Baupost Private Investments B-1, L.L.C.), (iii) Baupost Limited Partnership 1983 C-1 (being the parent entity of Baupost Private Investments C-1, L.L.C), (iv) Baupost Value Partners, L.P.-II (being the parent entity of Baupost Private Investments BVII-1, L.L.C), (v) HB Institutional Limited Partnership (being the parent entity of Baupost Private Investments H-1, L.L.C.), (vi) PB Institutional Limited Partnership (being the parent entity of Baupost Private Investments P-1, L.L.C.), (vii) YB Institutional Limited Partnership (being the parent entity of Baupost Private Investments Y-1, L.L.C.), (viii) Baupost Value Partners, L.P.-I (being the parent entity of Baupost Private Investments BVI-1, L.L.C), (ix) Baupost Value Partners, L.P.-III (being the parent entity of Baupost Private Investments BVIII-1, L.L.C.) and (x) Baupost Value Partners, L.P.-IV (being the parent entity of Baupost Private Investments BVIV-1, L.L.C.). Further, according to the notification, neither Seth Klarman nor any other entity under his control, other than (i) Baupost Private Investments A-1, L.L.C., (ii) Baupost Private Investments B-1, L.L.C, (iii) Baupost Private Investments C-1, L.L.C., (iv) Baupost Private Investments H-1, L.L.C., (v) Baupost Private Investments P-1, L.L.C., (vi) Baupost Private Investments Y-1, L.L.C., (vii) Baupost Private Investments BVI-1, L.L.C., (viii) Baupost Private Investments BVII-1, L.L.C., (ix) Baupost Private Investments BVIII-1, L.L.C. and (x) Baupost Private Investments BVIV-1, L.L.C., holds any shares or financial instruments in the Company. In Turku, December 22, 2015 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp. tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com DISTRIBUTION: NASDAQ OMX Helsinki Ltd Main Media